Affiliation:
1. From the Veterans Affairs Medical Center, Minneapolis, MN; Long Island Jewish Medical Center, New Hyde Park, and North Shore University Hospital, Manhasset, NY; Cancer and Leukemia Group B Statistical Center, Durham, NC; University of New Mexico Health Sciences Center, Albuquerque, NM; Fred Hutchinson Cancer Research Center, Seattle, WA; The Case Western Reserve University School of Medicine, Cleveland, OH; National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada; University...
Abstract
PURPOSE: Patients with chronic lymphocytic leukemia (CLL) may have disease transformation to non-Hodgkin’s lymphoma or prolymphocytic leukemia; however, development of therapy-related acute myeloid leukemia (t-AML) is unusual. A series of patients enrolled onto an intergroup CLL trial were examined for this complication. PATIENTS AND METHODS: A total of 544 previously untreated B-cell CLL patients were enrolled onto a randomized intergroup study comparing treatment with chlorambucil, fludarabine, or fludarabine plus chlorambucil. Case report forms from 521 patients were reviewed for t-AML. RESULTS: With a median follow-up of 4.2 years, six patients (1.2%) to date have developed therapy-related myelodysplastic syndrome (t-MDS; n = 3), t-AML (n = 2), or t-MDS evolving to t-AML (n = 1), from 27 to 53 months (median, 34 months) after study entry. This included five (3.5%) of 142 patients treated with fludarabine plus chlorambucil and one (0.5%) of 188 receiving fludarabine; no chlorambucil-treated patients developed t-MDS or t-AML (P = .007). At study entry, the median age among these six patients was 56 years (range, 44 to 72 years); three were male; the CLL Rai stage was I/II (n = 4) or III/IV (n = 2). Response to CLL therapy was complete (n = 4) or partial remission (n = 1) and stable disease (n = 1). Marrow cytogenetics, obtained in three of six cases at diagnosis of t-MDS or t-AML, were complex, with abnormalities in either or both chromosomes 5 and 7. Other abnormalities involved chromosomes X, 1, 8, 12, 17, and 19. Median survival after diagnosis of t-MDS/AML was 3.5 months (range, 0.5 to 10.1 months). CONCLUSION: Our findings raise the possibility that alkylator-purine analog combination therapy may increase the risk of therapy-related myeloid malignancies, which is of particular relevance with regard to ongoing trials using these combination therapies.
Publisher
American Society of Clinical Oncology (ASCO)
Reference45 articles.
1. Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia
2. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment
3. THERAPY-RELATED MYELOID LEUKEMIA
4. Greene MH, Hoover RN, Fraumein JF Jr: Subsequent cancer in patients with chronic lymphocytic leukemia: A possible immunologic mechanism. J Natl Cancer Inst 61: 337,1978-340,
5. Quaglino D, Lusvarghi E, Piccinini L, et al: The association between chronic lymphocytic leukemia and a solid tumor: A survey study of 258 cases of chronic lymphocytic leukemia covering an eleven year period. Haematologica 61: 456,1976-469,
Cited by
156 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献